Low-Dose Prophylactic Intravenous Immunoglobulin Does Not Prevent HLA Sensitization in Left Ventricular Assist Device Recipients

Annals of Thoracic Surgery

Volumn 82, Issue 3, 2006, Pages 889-893

  Drakos, Stavros G ^a,b   Kfoury, Abdallah G ^a   Long, James W ^a   Stringham, James C ^b,c   Fuller, Thomas C ^b   Nelson, Karl E ^a   Campbell, Beverly K ^a   Gilbert, Edward M ^b,c   Renlund, Dale G ^a,b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; RHESUS ANTIBODY;

ADULT; ARTICLE; ASSISTED CIRCULATION; BLOOD TRANSFUSION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART ASSIST DEVICE; HEART FAILURE; HLA SYSTEM; HUMAN; IMPLANTATION; INCIDENCE; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RHESUS IMMUNIZATION; RISK ASSESSMENT; SENSITIZATION; SURGEON;

ADULT; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HLA ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PULSATILE FLOW; RETROSPECTIVE STUDIES; SURFACE PROPERTIES; TREATMENT FAILURE;

EID: 33747378504     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2006.04.017     Document Type: Article

References (31)

1. Frazier O.H., Rose E.A., Oz M.C., et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 122 (2001) 1189-1195
2. Massad M.G., Cook D.J., Schmitt S.K., et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg 64 (1997) 1120-1125
3. McKenna Jr. D.H., Eastlund T., Segall M., Noreen H.J., and Park S. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 21 (2002) 1218-1224
4. Stringham J.C., Bull D.A., Fuller T.C., et al. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. J Heart Lung Transplant 18 (1999) 160-165
5. Smith J.D., Danskine A.J., Laylor R.M., Rose M.L., and Yacoub M.H. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heart and heart-lung transplantation. Transpl Immunol 1 (1993) 60-65
6. Lavee J., Kormos R.L., Duquesnoy R.J., et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 10 (1991) 921-930
7. Kobashigawa J.A., Sabad A., Drinkwater D., et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 94 (1996) II294-II297
8. Itescu S., Tung T.C., Burke E.M., et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 98 (1998) 786-793
9. Mehra M.R., Uber P.A., Uber W.E., Scott R.L., and Park M.H. Allosensitization in heart transplantation. implications and management strategies. Curr Opin Cardiol 18 (2003) 153-158
10. Fung Kee Fung K., Eason E., Crane J., et al. Prevention of Rh alloimmunization. J Obstet Gynaecol Can 25 (2003) 765-773
11. Nester T.A., Rumsey D.M., Howell C.C., et al. Prevention of immunization to D+ red blood cells with red blood cell exchange and intravenous Rh immune globulin. Transfusion 44 (2004) 1720-1723
12. Itescu S., Ankersmit J.H., Kocher A.A., and Schuster M.D. Immunobiology of left ventricular assist devices. Prog Cardiovasc Disa 43 (2000) 67-80
13. Rafii S., Oz M.C., Seldomridge J.A., et al. Characterization of hematopoietic cells arising on the textured surface of left ventricular assist devices. Ann Thorac Surg 60 (1995) 1627-1632
14. Schuster M., Kocher A., John R., et al. B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression. Hum Immunol 63 (2002) 211-220
15. Ankersmit H.J., Tugulea S., Spanier T., et al. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device. Lancet 354 (1999) 550-555
16. Zerbe T.R., Arena V.C., Kormos R.L., et al. Histocompatibility and other risk factors for histologic rejection of human cardiac allografts during the first three months following transplantation. Transplantation 52 (1991) 485-490
17. Rose E.A., Pepino P., Barr M.L., et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 11 (1992) S120-S123
18. De Mattos A.M., Head M.A., Everett J., et al. HLA-DR mismatching correlates with early cardiac allograft rejection, incidence, and graft survival when high confidence-level serological DR typing is used. Transplantation 57 (1994) 626-630
19. Lavee J., Kormos R.L., Duquesnoy R.J., et al. Influence of panel-reactive antibody and lymphocytotoxic cross-match on survival after heart transplantation. J Heart Lung Transplant 10 (1991) 921-930
20. Kobashigawa J.A., Sabad A., Drinkwater D., et al. Pretransplant panel reactive antibody screens. are they truly a marker for poor outcome after cardiac transplantation?. Circulation 94 (1996) II294-II297
21. Thompson J.S., Thacker II L.R., and Takemoto S. The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome. an analysis from the United Network of Organ Sharing Scientific Registry. Transplantation 69 (2000) 2178-2186
22. Jordan S.C., Vo A., Bunnapradist S., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 (2003) 631-636
23. Glotz D., Antoine C., Julia P., et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 17 (2004) 1-8
24. Rock G., and Buskard N.A. Therapeutic plasmapheresis. Curr Opin Hematol 3 (1996) 504-510
25. Larson D.F., Elkund D.K., Arabia F., et al. Plasmapheresis during cardiopulmonary bypass. a proposed treatment for presensitized cardiac transplantation patients. J Extra Corpor Technol 31 (1999) 177-183
26. Pisani B.A., Mullen G.M., Malinowska K., et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 18 (1999) 701-706
27. Itescu S., Burke E., Lietz K., et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 105 (2002) 1214-1219
28. Emmi L., and Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 23 Suppl 1 (2002) 1-8
29. Moazami N., Itescu S., Williams M.R., Argenziano M., Weinberg A., and Oz M.C. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. J Heart Lung Transplant 17 (1998) 876-880
30. Fauchet R., Genetet B., Gueguen M., Leguerrier A., Rioux C., and Logeais Y. Transfusion therapy and HLA antibody response in patients undergoing open heart surgery. Transfusion 22 (1982) 320-322
31. Drakos SG, Renlund DG, Long JW, et al. The impact of cellular blood product transfusion on allosensitization in LVAD recipients bridged to heart transplantation. Submitted for publication.